Update: Update on dyslipidemia

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 5, 2007, Pages 1581-1589

  Garg, Abhimanyu ^a,b   Simha, Vinaya ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTILIPEMIC AGENT; AROMATASE INHIBITOR; ASPARAGINASE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; BEXAROTENE; BEZAFIBRATE; CAPECITABINE; COLESTIPOL; CYCLOSPORIN; DIURETIC AGENT; DOCOSAHEXAENOIC ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GAMMA INTERFERON; GEMFIBROZIL; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; NICOTINIC ACID; PLACEBO; PRAVASTATIN; PROPOFOL; RAPAMYCIN; RETINOIC ACID DERIVATIVE; SIMVASTATIN; TAMOXIFEN; UNINDEXED DRUG; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; FAMILIAL DISEASE; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIA; INTESTINE CELL; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER CELL; LIVER TOXICITY; LOW DRUG DOSE; MONOGENIC DISORDER; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TRANSPORT; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; BLOOD; GENETICS; HYPERLIPIDEMIA; METABOLISM;

ANIMALS; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIAS;

EID: 34249855801     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0275     Document Type: Article

References (100)

1. Goldstein JL, Brown MS 1979 The LDL receptor locus and the genetics of familial hypercholesterolemia. Ann Rev Genet 13:259-289
2. Fouchier SW, Kastelein JJ, Defesche JC 2005 Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum Mutat 26:550-556
3. van Aalst-Cohen ES, Jansen AC, Tanck MW, Defesche JC, Trip MD, Lansberg PJ, Stalenhoef AF, Kastelein JJ 2006 Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 27:2240-2246
4. Humphries SE, Whittall RA, Hubbart CS, Maplebeck S, Cooper JA, Soutar AK, Naoumova R, Thompson GR, Seed M, Durrington PN, Miller JP, Betteridge DJ, Neil HA 2006 Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 43:943-949
5. Tosi I, Toledo-Leiva P, Neuwirth C, Naoumova RP, Soutar AK 2006 Genetic defects causing familial hypercholesterolaemia: Identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis, in press
6. Humphries SE, Talmud PJ 1995 Hyperlipidaemia associated with genetic variation in the apolipoprotein B gene. Curr Opin Lipidol 6:215-222
7. Cladaras C, Hadzopoulou-Cladaras M, Nolte RT, Atkinson D, Zannis VI 1986 The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms. EMBO J 5:3495-3507
8. Gasparovic J, Basistova Z, Fabryova L, Wsolova L, Vohnout B, Raslova K 2006 Familial defective apolipoprotein B-100 in Slovakia Are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity? Atherosclerosis, in press
9. Vega GL, Grundy SM 1986 In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 78:1410-1414
10. Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ 1989 Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 86:587-591
11. Soufi M, Sattler AM, Maerz W, Starke A, Herzum M, Maisch B, Schaefer JR 2004 A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis 174:11-16
12. Fouchier SW, Defesche JC, Kastelein JJ, Sijbrands EJ 2004 Familial defective apolipoprotein B versus familial hypercholesterolemia: an assessment of risk. Semin Vasc Med 4:259-264
13. Schaefer JR, Scharnagl H, Baumstark MW, Schweer H, Zech LA, Seyberth H, Winkler K, Steinmetz A, Marz W 1997 Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterio Thromb Vasc Biol 17:348-353
14. Gallagher JJ, Myant NB 1995 The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100. Atherosclerosis 115:263-272
15. Ceska R, Vrablik M, Horinek A 2000 Familial defective apolipoprotein B-100: a lesson from homozygous and heterozygous patients. Physiol Res 49 (Suppl 1):S125-S30
16. Marz W, Baumstark MW, Scharnagl H, Ruzicka V, Buxbaum S, Herwig J, Pohl T, Russ A, Schaaf L, Berg A, Bohles HJ, Usadel KH, Groß W 1993 Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor. J Clin Invest 92:2922-2933
17. Funke H, Rust S, Seedorf U, Brennhausen B, Chirazi A, Motti C, Assmann G 1992 Homozygosity for familial defective apolipoprotein B-100 (FDB) is associated with lower plasma cholesterol concentrations than homozygosity for familial hypercholestrolemia (FH). Circulation 86:I-691 (Abstract)
18. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derre A, Villeger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C 2003 Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156
19. Park SW, Moon YA, Horton JD 2004 Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/ kexin type 9a in mouse liver. J Biol Chem 279:50630-50638
20. Maxwell KN, Fisher EA, Breslow JL 2005 Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 102:2069-2074
21. Timms KM, Wagner S, Samuels ME, Forbey K, Goldfine H, Jammulapati S, Skolnick MH, Hopkins PN, Hunt SC, Shattuck DM 2004 A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 114:349-353
22. Leren TP 2004 Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 65:419-422
23. Varret M, Rabes JP, Saint-Jore B, Cenarro A, Marinoni JC, Civeira F, Devillers M, Krempf M, Coulon M, Thiart R, Kotze MJ, Schmidt H, Buzzi JC, Kostner GM, Bertolini S, Pocovi M, Rosa A, Farnier M, Martinez M, Junien C, Boileau C 1999 A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am J Hum Genet 64:1378-1387
24. Haddad L, Day IN, Hunt S, Williams RR, Humphries SE, Hopkins PN 1999 Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred. J Lipid Res 40:1113-1122
25. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH 2005 Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37:161-165
26. Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH 2006 Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272
27. Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, Calandra S, Bertolini S, Cossu F, Grishin N, Barnes R, Cohen JC, Hobbs HH 2001 Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292:1394-1398
28. Garuti R, Jones C, Li WP, Michaely P, Herz J, Gerard RD, Cohen JC, Hobbs HH 2005 The modular adaptor protein autosomal recessive hypercholesterolemia (ARH) promotes low density lipoprotein receptor clustering into clathrin-coated pits. J Biol Chem 280:40996-41004
29. Arca M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S, Calandra S, Ricci G, Glorioso N, Maioli M, Pintus P, Carru C, Cossu F, Cohen J, Hobbs HH 2002 Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 359:841-847
30. Harada-Shiba M, Takagi A, Miyamoto Y, Tsushima M, Ikeda Y, Yokoyama S, Yamamoto A 2003 Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 88:2541-2547
31. Abera AB, Marais AD, Raal FJ, Leisegang F, Jones S, George P, Henderson HE 2007 Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype. Clin Chim Acta 378(1-2):33-37
32. Pisciotta L, Oliva CP, Pes GM, Di Scala L, Bellocchio A, Fresa R, Cantafora A, Arca M, Calandra S, Bertolini S 2006 Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis 188:398-405
33. Jones C, Garuti R, Michaely P, Li WP, Maeda N, Cohen JC, Herz J, Hobbs HH 2007 Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia. J Clin Invest 117:165-174
34. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH 2000 Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290:1771-1775
35. Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK, Salen G, Dean M, Patel SB 2001 Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 27:79-83
36. Hazard SE, Patel SB 2007 Sterolins ABCG5 and ABCG8: regulators of whole body dietary sterols. Pflugers Arch 453:745-752
37. 1991 Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 303:893-896
38. Oliva CP, Pisciotta L, Li Volti G, Sambataro MP, Cantafora A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S 2005 Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterio Thromb Vasc Biol 25:411-417
39. Marcais C, Verges B, Charriere S, Pruneta V, Merlin M, Billon S, Perrot L, Drai J, Sassolas A, Pennacchio LA, Fruchart-Najib J, Fruchart JC, Durlach V, Moulin P 2005 Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 115:2862-2869
40. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J 2005 Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280:21553-21560
41. Merkel M, Heeren J 2005Give me A5 for lipoprotein hydrolysis! J Clin Invest 115:2694-2696
42. Agarwal AK, Garg A 2006 Genetic disorders of adipose tissue development, differentiation, and death. Ann Rev Genomics Hum Genet 7:175-199
43. Garg A 2004 Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234
44. Huertas-Vazquez A, Aguilar-Salinas C, Lusis AJ, Cantor RM, Canizales-Quinteros S, Lee JC, Mariana-Nunez L, Riba-Ramirez RM, Jokiaho A, Tusie-Luna T, Pajukanta P 2005 Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterio Thromb Vasc Biol 25:1985-1991
45. Ng MC, Miyake K, So WY, Poon EW, Lam VK, Li JK, Cox NJ, Bell GI, Chan JC 2005 The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia 48:2018-2024
46. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, Duan XJ, Soro-Paavonen A, Naukkarinen J, Saarela J, Laakso M, Ehnholm C, Taskinen MR, Peltonen L 2004 Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36:371-376
47. van der Vleuten GM, Isaacs A, Hijmans A, van Duijn CM, Stalenhoef AF, de Graaf J 2007 The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemia. J Lipid Res 48:193-200
48. Naukkarinen J, Ehnholm C, Peltonen L 2006 Genetics of familial combined hyperlipidemia. Curr Opin Lipidol 17:285-290
49. Suviolahti E, Lilja HE, Pajukanta P 2006 Unraveling the complex genetics of familial combined hyperlipidemia. Ann Med 38:337-351
50. Ikewaki K, Matsunaga A, Han H, Watanabe H, Endo A, Tohyama J, Kuno M, Mogi J, Sugimoto K, Tada N, Sasaki J, Mochizuki S 2004 A novel two nucleotide deletion in the apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. Atherosclerosis 172:39-45
51. Yokota H, Hashimoto Y, Okubo S, Yumoto M, Mashige F, Kawamura M, Kotani K, Usuki Y, Shimada S, Kitamura K, Nakahara K 2002 Apolipoprotein A-I deficiency with accumulated risk for CHD but no symptoms of CHD. Atherosclerosis 162:399-407
52. Pisciotta L, Miccoli R, Cantafora A, Calabresi L, Tarugi P, Alessandrini P, Bittolo Bon G, Franceschini G, Cortese C, Calandra S, Bertolini S 2003 Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency. Atherosclerosis 167:335-345
53. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J, Salvetti M, Monteduro C, Zulli R, Muiesan ML, Agabiti-Rosei E 2001 Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 103:1949-1954
54. von Eckardstein A, Funke H, Henke A, Altland K, Benninghoven A, Assmann G 1989 Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I. J Clin Invest 84:1722-1730
55. Strobl W, Jabs HU, Hayde M, Holzinger T, Assmann G, Widhalm K 1988 Apolipoprotein A-I (Glu 198 - Lys): a mutant of the major apolipoprotein of high-density lipoproteins occurring in a family with dyslipoproteinemia. Pediat Res 24:222-228
56. Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez A 2003 Genetics of HDL regulation in humans. Curr Opinion Lipidol 14:273-279
57. Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR 2003 Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterio Throm Vasc Biol 23:1322-1332
58. Hovingh GK, de Groot E, van der Steeg W, Boekholdt SM, Hutten BA, Kuivenhoven JA, Kastelein JJ 2005 Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 16:139-145
59. Ho Hong S, Rhyne J, Zeller K, Miller M 2002 Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim Biophys Acta 1587:60-64
60. Hovingh GK, Kuivenhoven JA, Bisoendial RJ, Groen AK, van Dam M, van Tol A, Wellington C, Hayden MR, Smelt AH, Kastelein JJ 2004 HDL deficiency and atherosclerosis: lessons from Tangier disease. J Intern Med 255:299-301
61. Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY, Collins JA, Roelants R, Tamasawa N, Stulc T, Suda T, Ceska R, Boucher B, Rondeau C, DeSouich C, Brooks-Wilson A, Molhuizen HO, Frohlich J, Genest Jr J, Hayden MR 2000 Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest 106:1263-1270
62. Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S 2006 Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 155:261-266
63. Milionis HJ, Liberopoulos EN, Elisaf MS 2001 Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus. Diabetes Metab 27:160-163
64. Bundred NJ 2005 The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 93(Suppl 1):S23-S27
65. Conte P, Frassoldati A 2007 Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective. Breast J 13:28-35
66. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62
67. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757
68. Keung YK, Rizk R, Wu XY, Cobos E 1999 Drug-induced hypertriglyceridemia with and without pancreatitis. South Med J 92:912-914
69. Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N 2006 Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 40:328-331
70. Bustamante SE, Appachi E 2006 Acute pancreatitis after anesthesia with propofol in a child with glycogen storage disease type IA. Paediatr Anaesth 16:680-683
71. 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
72. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, Trautwein EA, Josse RG, Leiter LA, Connelly PW 2003 Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 290:502-510
73. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, Pasternak RC, Smith Jr SC, Stone NJ 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239
74. Brown MS, Goldstein JL 2006 Biomedicine. Lowering LDL-not only how low, but how long? Science 311:1721-1723
75. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. 2002 Lancet 360:7-22
76. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM 2004 Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504
77. Hayward RA, Hofer TP, Vijan S 2006 Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 145:520-530
78. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435
79. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J 2005 High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294:2437-2445
80. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E 2004 Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292:1307-1316
81. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E 2006 Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48:438-445
82. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ 2007 Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356:148-156
83. Miller M, Seidler A, Moalemi A, Pearson TA 1998 Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 31:1252-1257
84. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F 1998 Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97:1029-1036
85. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW 2002 Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162:2597-2604
86. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A 1997 Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol 80:1125-1129
87. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR 1997 Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96:2137-2143
88. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849-1861
89. Stewart BF, Brown BG, Zhao XQ, Hillger LA, Sniderman AD, Dowdy A, Fisher LD, Albers JJ 1994 Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 23:899-906
90. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ 2001 Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592
91. Forrester JS, Shah PK 2006 Emerging strategies for increasing high-density lipoprotein. Am J Cardiol 98:1542-1549
92. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ 2004 Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterio Thromb Vasc Biol 24:490-497
93. Tanne JH 2006 Pfizer stops clinical trials of heart drug. BMJ 333:1237
94. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R 2003 Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290:2292-2300
95. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM 2006 Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 3:540-547
96. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK 2004 Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110:1701-1705
97. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, Fogelman AM 2005 Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circulation Res 97:524-532
98. Marks D, Thorogood M, Neil HA, Humphries SE 2003 A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168:1-14
99. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM 2007 Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356:1304-11316
100. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML 2007 Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med, in press